Resources
About Us
Home Report
Store
Cardiac Biomarkers Market
Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing ) - Global Forecast to 2031
Report ID:MRHC - 1041448 Pages: 165 Jan-2025 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe Cardiac Biomarkers Market was valued at $5.15 billion in 2023. This market is expected to reach $10.08 billion by 2031 from an estimated $5.57 billion in 2024, at a CAGR of 8.8% during the forecast period of 2024-2031.
Cardiac Biomarkers Market Size & Forecast
The growth of the cardiac biomarkers market is driven by the increasing prevalence of cardiovascular diseases, rising geriatric population, technological advancements in cardiac biomarkers, increasing healthcare expenditure, and increasing cardiovascular disease awareness programs. Furthermore, the introduction of novel biomarkers tests and integration of biomarkers in point-of-care testing are expected to generate growth opportunities for the stakeholders in this market.
Key Findings
- By Type: The Troponin Segment Dominated the Cardiac Biomarkers Market in 2024.
- By Application: The Myocardial Infarction Segment Dominated the Cardiac Biomarkers Market in 2024.
- By End User: The Laboratory Testing Dominated the Cardiac Biomarkers Market in 2024.
Cardiac biomarkers Market Growth Drivers
Increasing Prevalence of Cardiovascular Diseases and Rising Geriatric Population
The rising prevalence of cardiovascular diseases due to changing lifestyle factors such as poor diet intake, growing consumption of alcohol are the major driving factors of increasing cardiovascular disease cases. The rising cases of heart attack due to changing lifestyles, environmental factors, and growing geriatric population are contributing to the growth of the cardiac biomarker market. According to the World Health Organization (WHO), about 32% of global deaths, out of these, 85% were due to heart attack and stroke in 2019. Around 805,000 individuals in the U.S. are suffering from heart attack. Out of these 605,000 are a first heart attack (source: Centers for Disease Control and Prevention (CDC)). According to Heart Failure society of America stats 2024: Heart Failure Epidemiology and Outcomes Statistics, around 6.7 million Americans over the age of 20 living with heart failure, and this figure is expected to rise 8.7 million by 2030. These rising cases of cardiovascular diseases are expected to drive the demand for cardiac biomarkers in the market.
Additionally, the rising geriatric population is one of the major contributing factors to the growth of cardiac biomarkers market. According to the World Health Organization (WHO) the number and proportion of people aged 60 years and older is increasing. It is expected that it will increase to 1.4 billion by 2030 and 2.1 billion by 2050. There is a high incidence of heart related diseases shown in people due to rising age. This factor also creates a demand for cardiac biomarkers as preventive care diagnostic solution in the aged population. These factors are expected to increase the adoption of cardiac biomarkers and eventually drive the growth of the market.
Increasing Cardiovascular Disease Awareness Programs
The increasing awareness about cardiovascular diseases through different awareness programs is one of the major driving factors for the growth of the cardiac biomarkers market. The heart disease and stroke are majorly responsible factor for 1 in 4 deaths in the United States each year. In addition, 120 million people have high blood pressure, a major risk factor for heart disease and stroke and an increasingly common cause of pregnancy complications. To spread awareness among the population regarding cardiovascular diseases various organizations and institutes are running awareness campaigns and programs. The Heart Truth is a national education program that raises awareness about heart disease and its risk factors. This program is brought by National Heart, Lung, and Blood Institute (NHLBI) (U.S.). The aim is to spread awareness among the population about heart diseases and make positive changes in public health. It is expected that rising awareness programs are contributing to the high adoption of cardiac biomarkers as a preventive care solution in the market. These factors are expected to drive the growth of the cardiac biomarkers market.
Cardiac biomarkers Market Growth Trends
Trends Focus on Multi-Analyte Panels
Multianalyte panels combine multiple biomarkers which reflect various aspects of cardiovascular health. By analyzing multiple biomarkers simultaneously, these panels provide a more accurate and comprehensive assessment of cardiac conditions in patients. Additionally, these panels help healthcare providers to assess a patient's risk more effectively by evaluating several biomarkers which reflect different physiological processes, such as oxidative stress, inflammation, and myocardial injury. These panels also allow for more precise stratification of patients based on their risk of developing serious cardiac events. Moreover, early disease detection is crucial for preventing the progression of diseases like coronary artery disease (CAD) or heart failure which enables earlier and more effective interventions. These panels can also help in monitoring the progression of cardiovascular diseases over time by tracking multiple biomarkers related to disease severity and response to treatment. Healthcare providers can adjust treatment plans based on how the patient is evolving and ensuring optimal care. Thes factors are expected to drive the growth of the market and lead to higher adoption of cardiac biomarkers among the patients and healthcare providers.
Cardiac biomarkers Market Opportunities
Integration of Biomarkers in Point-of-Care Testing
Integration of biomarkers in point-of-care testing can create a growth of opportunities for cardiac biomarkers market. One of the primary advantages of POC testing is the ability to provide real-time results which allow healthcare providers to make immediate clinical decisions. For different cardiac conditions like heart attack rapid biomarker testing at the point of care can significantly reduce time of diagnosis, enables faster interventions, and results in better patient outcomes. It can be particularly valuable in emergency settings where timely diagnosis is critical. This capability of point-of-care testing can make biomarkers a routine part of emergency care and drive demand for such tests.
Moreover, convenience offered by these solutions can increase the adoption of cardiac biomarkers in the market. POC testing can be performed in various settings, including emergency rooms, doctor's offices, ambulances, and even at home. Patients can receive quick results without needing to wait for lab-based testing or travel to medical centers. This convenience helps in improving patient satisfaction and encourages greater utilization of cardiac biomarkers, expanding their market reach. These factors are expected to create growth opportunities for the cardiac biomarkers market.
Cardiac Biomarkers Market Analysis: Top Market Opportunity
By Type: In 2024, Troponin Segment Dominated the Cardiac Biomarkers Market
Based on type, the cardiac biomarkers market is segmented into Troponin, Creatine Kinase MB (CK-MB), Myoglobin, B-Type Natriuretic Peptide (BNP), N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) and Other Types. In 2024, the troponin segment accounted for the largest share of 51.7 of the cardiac biomarkers market. The large share of this segment is attributed to the high sensitivity and specificity in detecting Myocardial infarction, key features of troponin, new product launches, major players offering troponin testing products, and advancements in high sensitivity troponin tests.
However, the B-type natriuretic peptide (BNP) segment is expected to grow at the highest CAGR of during the forecast period of 2024 to 2031. Rising heart failure cases, collaboration with pharmaceutical companies, clinical guidelines are highly recommended BNP for diagnosis and monitoring, and advancements in BNP assays. These factors contribute to the fastest growth of the segment. For instance, in January 2022, Arbor Assays, Inc. (U.S.) has launched a new human B-Type Natriuretic Peptide (BNP) ELISA kits to detect BNP and proBNP for heart failure and cardiac dysfunction.
By End User: In 2024, Laboratory Testing Segment Dominated the Cardiac Biomarkers Market
Based on end user, the global cardiac biomarkers market is segmented into laboratory testing and point-of care testing. In 2024, the laboratory testing segment accounted for the largest share of 59.7% of the global cardiac biomarkers market. The large market share of this segment is attributed to the rising number of diagnostics laboratories, increasing awareness about early disease diagnosis, availability of skilled professionals, and increasing investments in developing healthcare infrastructure.
Geographic Analysis
North America Dominated the Cardiac biomarkers Market in 2024
In 2024, North America accounted for the largest share of 39.5% of the global cardiac biomarkers market. The region’s large share of the cardiac biomarkers market is primarily attributed to increasing prevalence of cardiovascular diseases coupled with rising geriatric population, increasing sedentary lifestyle, rising consumption of alcohol & caffeine, well-established healthcare system, high awareness of cardiovascular diseases, high healthcare expenditure, presence of major key players in this region. As the number of cases of cardiovascular disease rises, consequently increases the demand for diagnostic tools such as cardiac biomarkers in the U.S.
However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period. This market’s growth is attributed to increasing burden of patients with CVDs, rising urbanization, changing lifestyle, rising healthcare expenditure, developing healthcare infrastructure, increasing geriatric population, rising focus of the key players to expand in emerging countries like China & India. According to the Journal of the American College of Cardiology (JACC), CVD mortality rates among countries in High-income Asia Pacific ranges from 72.7 to 252.6 per 100,000 in 2022. Out of the twenty-one regions, high-income Asia Pacific was ranked 21st in 2022 for age-standardized CVD mortality. This shows a high burden of deaths in the region due to cardiovascular diseases.
Cardiac Biomarkers Market: Key Companies
The report includes a competitive landscape based on an extensive assessment of the product offerings, geographic presence, and key strategic developments of leading market players (2021–2024). The key players operating in the cardiac biomarkers market are Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), BioMérieux SA (France), Danaher Corporation (U.S.), Creative Diagnostics (U.S.), Life Diagnostics, Inc. (U.S.), Randox Laboratories Ltd. (U.K), Becton, Dickinson and Company (U.S.), and QuidelOrtho Corporation (U.S.).
Cardiac Biomarkers Market Overview: Latest Developments from Key Industry Players
- In October 2024, Siemens Healthineers received FDA approval of a new progressive claim for Atellica IM high-sensitivity troponin I (TnIH) test for predicting Heart Attack.
- In June 2024, Siemens Healthineers introduced the NT-proBNPII (PBNPII) assay to its cardiac portfolio on the Atellica Solution for diagnosing heart failure.
- In May 2024, Beckman Coulter, Inc. (U.S.) received FDA approval for its Access NT-proBNP (N-terminal Pro B-type Natriuretic Peptide) assay for the examination of heart failure in less than 11 minutes on Beckman Coulter DxI 9000 Immunoassay Analyzer.
- In April 2024, Roche Diagnostics India launched point-of-care (PoC) NT-proBNP test for screening of diabetes in patients at a risk of cardiovascular diseases such as heart failure.
- In April 2023, Bio-Rad launched Cardiac Advance quality controls for high sensitivity troponin testing.
- In December 2022, QuidelOrtho Corporation received approval from Health Canada for Quidel TriageTrue High-Sensitivity Troponin I Test for commercial use in Canada to aid in the diagnosis of myocardial infarction.
- In May 2022, Quidel Corporation and Ortho Clinical Diagnostics Holdings plc is merged to form QuidelOrtho Corporation to provide in vitro diagnostics solutions.
- In July 2021, Beckman Coulter, Inc. (U.S.) signed an agreement with QuidelOrtho Corporation (U.S.) to obtain Beckman Coulter all manufacturing, distribution, and sales rights for BNP assay. This agreement aims to improve Beckman Coulter’s capabilities in cardiovascular diagnostics.
Cardiac Biomarkers Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
165 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
8.8% |
|
Market Size (2024) |
$5.57 billion |
|
Market Size (2031) |
$10.08 Billion |
|
Segments Covered |
By Type
By Application
By End User
|
|
Countries Covered |
North America (U.S., Canada), Europe (Germany, France, Italy, U.K., Spain, Switzerland, Netherlands, Rest of Europe), Asia-Pacific (Japan, China, India, South Korea, Australia, Rest of APAC), Latin America (Brazil, Mexico, Rest of Latin America), and the Middle East & Africa |
|
Key Companies Profiled |
Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), BioMérieux SA (France), Danaher Corporation (U.S.), Creative Diagnostics (U.S.), Life Diagnostics, Inc. (U.S.), Randox Laboratories Ltd. (U.K), Becton, Dickinson and Company (U.S.), and QuidelOrtho Corporation (U.S.). |
Key questions answered in the cardiac biomarkers market report:
The cardiac biomarkers market size was valued at $5.15 billion in 2023.
The market is projected to grow from $5.57 billion in 2024 to $10.08 billion by 2031.
The cardiac biomarkers market analysis indicates a significant growth to reach $10.08 billion by 2031, at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.
The key players operating in the cardiac biomarkers market are Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), BioMérieux SA (France), Danaher Corporation (U.S.), Creative Diagnostics (U.S.), Life Diagnostics, Inc.?(U.S.), Randox Laboratories Ltd. (U.K), Becton, Dickinson and Company (U.S.), and QuidelOrtho Corporation (U.S.).
A prominent market trend in cardiac biomarkers is the focus on multi-analyte panels.
By Type: The troponin segment is forecasted to hold the largest market share.
By Application, the myocardial Infarction segment is forecasted to hold the largest market share.
By End User, the laboratory testing segment is forecasted to hold the largest Market share.
The primary drivers of cardiac biomarkers market growth include increasing prevalence of cardiovascular diseases, rising geriatric population, technological advancements in cardiac biomarkers, increasing healthcare expenditure, and increasing cardiovascular disease awareness programs.
1. Market Definition & Scope
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for The Study
3. Executive Summary
4. Factors Affecting Market Growth
4.1. Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Cardiovascular Diseases and Rising Geriatric Population
4.2.2. Technological Advancements in Cardiac Biomarkers
4.2.3. Increasing Healthcare Expenditure
4.2.4. Increasing Cardiovascular Disease Awareness Programs
4.3. Restraints
4.3.1. Limited Specificity and Sensitivity of Biomarkers
4.3.2. High Cost of Biomarker Testing
4.4. Opportunity
4.4.1. Introduction of Novel Biomarker Tests
4.4.2. Integration of Biomarkers in Point-of-Care Testing
4.5. Challenges
4.5.1. Alternative Diagnostic Technologies
4.6. Trends
4.6.1. Focus on Multi-Analyte Panels
4.7. Regulatory Analysis
4.8. Porter’s Five Forces Analysis
5. Cardiac Biomarkers Market Assessment—By Type
5.1. Overview
5.2. Troponin
5.3. Creatine Kinase Mb (CK-Mb)
5.4. Myoglobin
5.5. B-Type Natriuretic Peptide (BNP)
5.6. N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)
5.7. Other Types
6. Cardiac Biomarkers Market Assessment—By Application
6.1. Overview
6.2. Myocardial Infarction
6.3. Acute Coronary Syndrome
6.4. Congestive Heart Failure
6.5. Other Applications
7. Cardiac Biomarkers Market Assessment—By End User
7.1. Overview
7.2. Laboratory Testing
7.3. Point-of-Care Testing
8. Cardiac Biomarkers Market Assessment—By Geography
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. UK
8.3.4. Italy
8.3.5. Spain
8.3.6. Switzerland
8.3.7. Rest of Europe (RoE)
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. Rest of Asia-Pacific (RoAPAC)
8.5. Latin America
8.6. Middle East & Africa
9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share/Ranking Analysis, By Key Players, 2023
10. Company Profiles
(Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
10.1. F. Hoffman-La-Roche Ltd (Switzerland)
10.2. Bio-Rad Laboratories, Inc. (U.S.)
10.3. Abbott Laboratories (U.S.)
10.4. Thermo Fisher Scientific Inc. (U.S.)
10.5. Siemens Healthineer AG (Germany)
10.6. Danaher Corporation (U.S.)
10.7. bioMerieux SA (France)
10.8. Becton, Dickinson and Company (U.S.)
10.9. Life Diagnostics, Inc. (U.S.)
10.10. Creative Diagnostics (U.S.)
10.11. Randox Laboratories Ltd (U.K.)
10.12. QuidelOrtho Corporation (U.S.)
(Note: SWOT Analysis will be provided for the top 5 companies)*
11. Appendix
11.1. Available Customization
11.2. Related Reports
List of Tables
Table 1. Key Government Regulatory Agencies
Table 2. Cardiac Biomarker Types: Advantages & Disadvantages
Table 3. Global Cardiac Biomarkers Market Size, By Type, 2022-2031 (USD Million)
Table 4. Global Troponin Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
Table 5. Global Creatine Kinase Mb (Ck-Mb) Biomarkers Market, By Country/ Region, 2022-2031 (USD Million)
Table 6. Global Myoglobin Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
Table 7. Global BNP Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
Table 8. Difference Between BNP and NT-proBNP
Table 9. Global NT-proBNP Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
Table 10. Global Other Biomarker Types Market, By Country/Region, 2022-2031 (USD Million)
Table 11. Global Cardiac Biomarkers Market Size, By Application, 2022-2031 (USD Million)
Table 12. Global Cardiac Biomarkers Market for Myocardial Infarction, By Country/Region, 2022-2031 (USD Million)
Table 13. Global Cardiac Biomarkers Market for Acute Coronary Syndrome, By Country/Region, 2022-2031 (USD Million)
Table 14. Global Cardiac Biomarkers Market for Congestive Heart Failure, By Country/Region, 2022-2031 (USD Million)
Table 15. Global Cardiac Biomarkers Market for Other Application, By Country/Region, 2022-2031 (USD Million)
Table 16. Global Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
Table 17. Global Cardiac Biomarkers Market for Laboratory Testing, By Country/Region, 2021–2031 (USD Million)
Table 18. Global Cardiac Biomarkers Market for Point-of-Care Testing, By Country/Region, 2021–2031 (USD Million)
Table 19. Global Cardiac Biomarkers Market, By Country/Region, 2022–2031 (USD Million)
Table 20. North America: Cardiac Biomarkers Market, By Country, 2022-2031 (USD Million)
Table 21. North America: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 22. North America: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 23. North America: Cardiac Biomarkers Market, By End Use, 2022–2031 (USD Million)
Table 24. U.S.: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 25. U.S.: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 26. U.S.: Cardiac Biomarkers Market, By End Use, 2022–2031 (USD Million)
Table 27. Canada: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 28. Canada: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 29. Canada: Cardiac Biomarkers Market, By End Use, 2022–2031 (USD Million)
Table 30. Europe: Cardiac Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
Table 31. Europe: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 32. Europe: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 33. Europe: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 34. Germany: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 35. Germany: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 36. Germany: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 37. France: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 38. France: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 39. France: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 40. U.K.: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 41. U.K.: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 42. U.K.: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 43. Italy: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 44. Italy: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 45. Italy: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 46. Spain: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 47. Spain: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 48. Spain: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 49. Switzerland: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 50. Switzerland: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million
Table 51. Switzerland: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 52. Rest of Europe: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 53. Rest of Europe: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 54. Rest of Europe: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 55. Asia-Pacific: Cardiac Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
Table 56. Asia-Pacific: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 57. Asia-Pacific: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 58. Asia-Pacific: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 59. Japan: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 60. Japan: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 61. Japan: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 62. China: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 63. China: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 64. China: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 65. India: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 66. India: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 67. India: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 68. Australia: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 69. Australia: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 70. Australia: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 71. Rest of Asia Pacific: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 72. Rest of Asia Pacific: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 73. Rest of Asia Pacific: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 74. Latin America: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 75. Latin America: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 76. Latin America: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 77. Middle East & Africa: Cardiac Biomarkers Market, By Type, 2022–2031 (USD Million)
Table 78. Middle East & Africa: Cardiac Biomarkers Market, By Application, 2022–2031 (USD Million)
Table 79. Middle East & Africa: Cardiac Biomarkers Market, By End User, 2022–2031 (USD Million)
Table 80. Recent Developments, By Company, 2021-2024
List of Figures
Figure 1. Market Ecosystem
Figure 2. Secondary Sources referenced for this study
Figure 3. Primary Research Techniques
Figure 4. Key Executives Interviewed
Figure 5. Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6. Market Sizing & Growth Forecast Approach
Figure 7. Global Cardiac biomarkers Market, By Type, 2024 VS. 2031 (USD Million)
Figure 8. Global Cardiac biomarkers Market, By Application, 2024 VS. 2031 (USD Million)
Figure 9. Global Cardiac biomarkers Market, By End User, 2024 VS. 2031 (USD Million)
Figure 10. Global Cardiac biomarkers Market, By Geography, 2024 VS. 2031 (USD Million)
Figure 11. Impact Analysis of Market Dynamics
Figure 12. USFDA regulatory pathways for cardiac biomarkers
Figure 13. EU regulatry pathway – IVDR 2017/746
Figure 14. China: medical device classification and premarket requirements for crdaiac biomarkers products
Figure 15. Porter's Five Forces Analysis: cardiac biomarkers market
Figure 16. Global Cardiac biomarkers Market, By Type, 2024 VS. 2031 (USD Million)
Figure 17. Global Cardiac biomarkers Market, By Application, 2024 VS. 2031 (USD Million)
Figure 18. Global Cardiac biomarkers Market, By End User, 2024 VS. 2031 (USD Million)
Figure 19. Global pharmaceutical R&D spending, 2012-2026 (USD Billion)
Figure 20. Global Cardiac biomarkers Market, By Geography, 2024 VS. 2031 (USD Million)
Figure 21. North America: Cardiac biomarkers Market Snapshot
Figure 22. U.S. population aged 65 years and above, 2022-2026 (million)
Figure 23. U.S.: cardiovascular diseases prevalence rate in the population, 2021-2035
Figure 24. Europe: Cardiac biomarkers Market Snapshot
Figure 25. Asia Pacific: Cardiac biomarkers Market Snapshot
Figure 26. Latin America: Cardiac biomarkers Market Snapshot
Figure 27. Middle East & Africa: Cardiac biomarkers Market Snapshot
Figure 28. Key Growth Strategies Adopted By Leading Players, 2021—2024
Figure 29. Cardiac biomarkers Market: Competitive Benchmarking, By Type
Figure 30. Cardiac biomarkers Market: Competitive Benchmarking, By Region
Figure 31. Cardiac biomarkers Market: Competitive Dashboard
Figure 32. Cardiac biomarkers Market: Market Share Analysis, By Key Players (2023)
Figure 33. F. Hoffman-La-Roche Ltd: Financial Snapshot (2023)
Figure 34. Bio-Rad Laboratories, Inc.: Financial SNAPSHOT (2023)
Figure 35. Abbott Laboratories: Financial Snapshot (2023)
Figure 36. Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
Figure 37. Siemens Healthineer AG: Financial Snapshot (2024)
Figure 38. Danaher Corporation: Financial Snapshot (2023)
Figure 39. bioMerieux SA: Financial Snapshot (2023)
FIGURE 40. Becton, Dickinson and Company: FINANCIAL SNAPSHOT (2024)
Figure 41. QuidelOrtho Corporation: FINANCIAL SNAPSHOT (2023)
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Biomarkers Market - Global Opportunity Analysis And Industry Forecast (2024-2031)
Published Date: May-2024
Cardiac Pacemaker Devices Market - Global Opportunity Analysis and Industry Forecast (2021-2028)
Published Date: Sep-2021
Home Medical Equipment Market - Global Opportunity Analysis and Industry Forecast (2023-2030)
Published Date: Jun-2023
